Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof

A technology for cardiovascular and cerebrovascular diseases and compositions, applied in the fields of cardiovascular system diseases, drug combinations, blood diseases, etc., can solve the problem of elevated serum superoxide dismutase activity in patients with coronary heart disease, difficulty in controlling hygienic indicators, and reduce peroxidation Lipid content and other issues, to achieve strong pharmacological effects, overcome large fluctuations in curative effect, and clear ingredients

Inactive Publication Date: 2007-05-30
BEIJING QI YUAN YI DE PHARMA RESEARCH CENTER
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Acanthopanax injection is widely used in the treatment of cardiovascular and cerebrovascular diseases. Acanthopanax glycosides are its main physiologically active components. Modern pharmacology proves that Acanthopanax glycosides can dilate coronary arteries, increase coronary blood flow, slow down Heart rhythm and inhibition of cardiac contractility, increase serum superoxide dismutase activity in patients with coronary heart disease, reduce lipid peroxide content, increase tissue plasminogen activator and tissue plasminogen activator inhibition in patients Drugs, improve fibrinolytic function, expand cerebral blood vessels, improve brain oxygen supply, anti-tumor, anti-aging, anti-fatigue, hypoglycemic, hypolipidemic, and improve oxygen free radical metabolism disorders and other pharmacological effects. , not only the quality is difficult to guarantee, the dosage is large, but also the hygienic indicators are difficult to control; dipyridamole has antithrombotic properties, inhibits platelet aggregation, inhibits phosphodiesterase in various tissues, and inhibits the formation of thromboxane A2. Enhance functions such as endogenous PGI2, but because there is no absolute advantage in cardiovascular and cerebrovascular diseases, and there are certain side effects, it is limited in clinical use; Glycosides can be directly used as medicine, and dipyridamole is compatible to examine its molding process and drug effect. Small, less toxic and side effects of pharmaceutical preparations

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 2

[0069] Embodiment 2 of the present invention: dipyridamole 2g eleutherosides 80g

[0070] Take dipyridamole, add water for injection, add 2.5% tartaric acid and stir to dissolve it, and prepare the liquid medicine for later use; take total glucosides of Acanthopanax, add appropriate amount of water for injection and stir it to dissolve, and make the medicine liquid ready for later use; Add 0.6% activated carbon for needles by volume, boil, keep boiling slightly for 30 minutes, filter slightly cold, add an appropriate amount of water for injection to the filtrate, adjust the pH value to 4.5-6.0, boil, refrigerate at 4°C overnight, add water for injection to the full amount, and filter coarsely , finely filtered, packed into ampoules, sealed and sterilized to obtain 40 parts of eleutherosides and 1 part of dipyridamole small-volume injection or concentrated solution for injection.

Embodiment 3

[0071] Embodiment 3 of the present invention: dipyridamole 1g eleutherosides 100g

[0072] Take dipyridamole, add water for injection, add 0.5% tartaric acid and stir to dissolve it, and prepare the liquid for later use; take total glucosides of Acanthopanax, add an appropriate amount of water for injection to dissolve, and make the liquid for later use; combine the above two liquids, and add a specified amount of Glucose or sodium chloride, mix and dissolve, add 1.0% activated carbon for needles according to the volume, boil, keep boiling slightly for 30 minutes, filter slightly cold, add water for injection to the filtrate to an appropriate amount, adjust the pH value to 4.5-6.0, boil, 4°C Refrigerate overnight, coarsely filter, finely filter, add water for injection to the full amount, subpackage, and sterilize to obtain glucose or sodium chloride intravenous infusion containing 1 part of dipyridamole and 100 parts of eleutherosides.

Embodiment 4

[0073] Embodiment 4 of the present invention: dipyridamole 25g eleutherosides 25g

[0074] Take dipyridamole, add water for injection, add 0.2% citric acid and stir to dissolve, and prepare the liquid for later use; take total glucosides of Acanthopanax, add appropriate amount of water for injection, stir to dissolve, and prepare the liquid for later use; combine the two liquids above , adjust the pH value to 4.5-6.0, add water for injection to the specified amount, mix well, add 0.6% activated carbon for needles, boil for 30 minutes, coarse filter, then filter with 0.45μm and 0.22μm microporous membranes, and pack In the enamel tray, freeze-dry, the equilibrium time of the first stage is 1.5 hours when the equilibrium freezing temperature is 0°C, that is, the time when the shelf temperature is basically consistent with the product temperature; the second stage is from 0°C to the lowest eutectic temperature When the temperature is -16°C, it takes 2 hours to balance the tempera...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, its preparing process and quality control method, wherein Dipyridamole and one or two of acanthopanax root glycosides to obtain various dose forms of injections and oral administration preparations. The preparation of the composition is mainly used for treating transient cerebral ischemia, cerebral arteriosclerosis, brain thrombogenesis, cerebral embolism, coronary disease, angina pectoris combined neurasthenia and climacteric metancholia. The preparation of the invention has the advantages of high purity, ensured constituents, controllable quality, improved curative effect, wider range of safely, and less fluctuation of treatment effects.

Description

technical field [0001] The invention relates to a pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, a preparation method and a quality control method thereof, and belongs to the technical field of medicines. technical background [0002] At present, about 4 million people die from cardiovascular and cerebrovascular diseases in my country every year, accounting for more than 3 / 5 of the death toll, and it has become the primary factor threatening human health. Although there are a large number of Chinese and Western medicine interviews at present, with the continuous change of disease spectrum and the arrival of aging age, the current medicine continues to show its limitations. Therefore, research and development of medicines for the treatment of cardiovascular and cerebrovascular diseases are always Become the focus and hot spot of people's attention. [0003] Acanthopanax injection is widely used in the treatment of cardiovascular and cere...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/254A61K31/7048A61K31/519A61K9/08A61K9/10A61K9/14A61K9/16A61K9/19A61K9/20A61K9/48A61K9/70A61P9/10A61P9/00A61P7/02A61P25/20A61P15/14G01N30/02G01N33/15
Inventor 于文风
Owner BEIJING QI YUAN YI DE PHARMA RESEARCH CENTER
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap